期刊文献+

拓普替康治疗卵巢癌的循证评价

Evidence - based Management of topotecan for patients with ovarian cancer
下载PDF
导出
摘要 目的采用循证医学的方法评价拓普替康治疗卵巢癌的效果和安全性。方法采用Cochrane系统评价方法,检索Cochrane图书馆,MEDLINE,CENTRAL,CNKI,VIP,CBMDISC等电子资料库,搜集关于拓普替康治疗卵巢癌的系统评价、临床随机对照试验等,并对所获取的证据进行质量评价。结果检索并纳入7篇临床随机对照试验,1篇系统评价。根据临床问题,对所查证据进行了评价。结论拓普替康与紫杉醇、甲基化脂质体阿霉素、吉西他滨等化疗药具有相似的治疗作用,是一种有效的治疗卵巢癌的二线化疗药物。 Objective Method of evidence - based medicine were used to discuss the effectiveness and safety of topo- tecan in the treatment of women with ovarian cancer. Methods To find the current best evidence of management of topotcean for patients with ovarian cancer,we have searched the Cochrane Library, MEDLINE, Cochrane Central Register of Controlled Trials(CENTRAL) , China National Knowledge Infrastructure databases(CNKI) , VIP, CBMDISC, in order to get the systematic review and randomized controlled trails(RCT) of management of topotecan for patients with ovarian cancer, and further criti- cally apprcased the available evidence. Results Seven RCT and one systematic review had been selected. Based on the clinical problem,we had searched for and asscessed the evidence. Conclusion Topotecan appears to have a similar level of effec- tiveness as paelitaxel and pcgylated liposomal doxorubiein(PLD) , though with different patterns of side effects.
作者 陈洪
出处 《中国医学创新》 CAS 2010年第18期11-13,共3页 Medical Innovation of China
关键词 拓普替康 卵巢癌 循证治疗 I艋床证据 Topotecan Ovarian cancer Evidence - based treatment Clinical evidence
  • 相关文献

参考文献7

  • 1董碧蓉.循证实践文章撰写模式与问题探讨[J].中国循证医学杂志,2005,5(7):562-565. 被引量:4
  • 2Bookman MA,Brady MF,McGuire WP,et al.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer:a Phase Ⅲ Trial of the Gynecologic Cancer Intergroup.J Clin Oncol.2009,27(9):1419-1425.
  • 3Gore M,Rustin G,Schuller J,et al.Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.British Journal of Cancer,2001,84(8):1043-1046.
  • 4Huinink W,Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal Clinical Oncology,1997,15(6):2183-2193.
  • 5Gordon AN,Fleagle JT,Guthrie D,et al.Recurrent epithelial ovarian carcinoma:a randomized phase Ⅲ study of pegylated liposomal doxorubicin versus topotecan.Journal Clinical Oncology,2001,19(14):3312-3322.
  • 6Hoskins P,Eisenhauer E,Vergote I,et al.Phase Ⅱ feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer:a National Cancer Institute of Canada Clinical Trials Group Study.Journal Clinical Oncology,2000,18(24):4038-4044.
  • 7De Placido S,Scambia G,Di Vagno G,et al.Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer:Multicenter Italian Trials in Ovarian Cancer(MITO-1) randomized study.Journal Clinical Oncology,2004,22(13):2635-2642.

二级参考文献3

  • 1刘雪梅,蔡羽嘉,杜亮,陈霖.对撰写循证实践文章的一点建议[J].中国循证医学杂志,2004,4(8):578-578. 被引量:2
  • 2Sackett DL, Richardson WS, Rosenberg W. Evidence-Based Medicine How to Practice & Teach EBM[M]. New York: Churchill Livingstone Inco, 1997; 91-96.
  • 3王家良.临床流行病学--临床科研设计、衡量与评价[M],第2版[M].北京:人民卫生出版社,2003.133-194.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部